{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:38:19Z","timestamp":1790393899516,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,24]]},"DOI":"10.7759\/cureus.95338","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T16:59:37Z","timestamp":1761325177000},"source":"Crossref","is-referenced-by-count":1,"title":["Current Therapeutic Strategies for FLT3-Mutated Acute Myeloid Leukemia: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Lainee","family":"Swanson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliena","family":"Liaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delbert","family":"Abi Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Duriancik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S279736","article-title":"What does the economic burden of acute myeloid leukemia treatment look like for the next decade? An analysis of key findings, challenges and recommendations","volume":"12","author":"Forsythe A","year":"2021","unstructured":"Forsythe A, Sandman K. What does the economic burden of acute myeloid leukemia treatment look like for the next decade? An analysis of key findings, challenges and recommendations. J Blood Med. 2021, 12:245-55. 10.2147\/JBM.S279736","journal-title":"J Blood Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis RM","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019, 36:70-87. 10.1016\/j.blre.2019.04.005","journal-title":"Blood Rev"},{"key":"ref3","article-title":"Chronic Myelogenous Leukemia","author":"Eden RE","year":"2023","unstructured":"Eden RE, Coviello JM. Chronic Myelogenous Leukemia. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v12.i2.69","article-title":"Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: a literature review","volume":"12","author":"Sampaio MM","year":"2021","unstructured":"Sampaio MM, Santos ML, Marques HS, et al.. Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: a literature review. World J Clin Oncol. 2021, 12:69-94. 10.5306\/wjco.v12.i2.69","journal-title":"World J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner H","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, et al.. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017, 129:424-47. 10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"key":"ref6","article-title":"Leukemia","author":"Chennamadhavuni A","year":"2023","unstructured":"Chennamadhavuni A, Lyengar V, Mukkamalla SKR, Shimanovsky A. Leukemia. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400756","article-title":"Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia","volume":"11","author":"Kiyoi H","year":"1997","unstructured":"Kiyoi H, Naoe T, Yokota S, et al.. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia. 1997, 11:1447-52. 10.1038\/sj.leu.2400756","journal-title":"Leukemia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.1.89","article-title":"Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia","volume":"97","author":"Meshinchi S","year":"2001","unstructured":"Meshinchi S, Woods WG, Stirewalt DL, et al.. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001, 97:89-94. 10.1182\/blood.v97.1.89","journal-title":"Blood"},{"key":"ref9","article-title":"Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia","volume":"10","author":"Nakao M","year":"1996","unstructured":"Nakao M, Yokota S, Iwai T, et al.. Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia. Leukemia. 1996, 10:1911-8.","journal-title":"Leukemia"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400812","article-title":"Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines","volume":"11","author":"Yokota S","year":"1997","unstructured":"Yokota S, Kiyoi H, Nakao M, et al.. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia. 1997, 11:1605-9. 10.1038\/sj.leu.2400812","journal-title":"Leukemia"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143429","article-title":"Targeting tyrosine kinases in acute myeloid leukemia: why, who and how?","volume":"20","author":"Fernandez S","year":"2019","unstructured":"Fernandez S, Desplat V, Villacreces A, et al.. Targeting tyrosine kinases in acute myeloid leukemia: why, who and how?. Int J Mol Sci. 2019, 20:3429. 10.3390\/ijms20143429","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02850.x","article-title":"Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia","volume":"113","author":"Abu-Duhier FM","year":"2001","unstructured":"Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol. 2001, 113:983-8. 10.1046\/j.1365-2141.2001.02850.x","journal-title":"Br J Haematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies","volume":"97","author":"Yamamoto Y","year":"2001","unstructured":"Yamamoto Y, Kiyoi H, Nakano Y, et al.. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001, 97:2434-9. 10.1182\/blood.v97.8.2434","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-like tyrosine kinase 3\/FLT3: from basic science to clinical implications","volume":"99","author":"Kazi JU","year":"2019","unstructured":"Kazi JU, R\u00f6nnstrand L. FMS-like tyrosine kinase 3\/FLT3: from basic science to clinical implications. Physiol Rev. 2019, 99:1433-66. 10.1152\/physrev.00029.2018","journal-title":"Physiol Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-4-13","article-title":"Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications","volume":"4","author":"Takahashi S","year":"2011","unstructured":"Takahashi S. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J Hematol Oncol. 2011, 4:13. 10.1186\/1756-8722-4-13","journal-title":"J Hematol Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402740","article-title":"FLT3 mutations in acute myeloid leukemia cell lines","volume":"17","author":"Quentmeier H","year":"2003","unstructured":"Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia. 2003, 17:120-4. 10.1038\/sj.leu.2402740","journal-title":"Leukemia"},{"key":"ref17","unstructured":"DepMap 25Q2 public. (2025). Accessed. September 3, 2025: https:\/\/depmap.org\/portal\/data_page\/?tab=allData."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the cancer cell line encyclopedia","volume":"569","author":"Ghandi M","year":"2019","unstructured":"Ghandi M, Huang FW, Jan\u00e9-Valbuena J, et al.. Next-generation characterization of the cancer cell line encyclopedia. Nature. 2019, 569:503-8. 10.1038\/s41586-019-1186-3","journal-title":"Nature"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1045","article-title":"The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3","volume":"101","author":"Spiekermann K","year":"2003","unstructured":"Spiekermann K, Dirschinger RJ, Schwab R, et al.. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood. 2003, 101:1494-504. 10.1182\/blood-2002-04-1045","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910410324","article-title":"Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes","volume":"41","author":"Ziegler-Heitbrock HW","year":"1988","unstructured":"Ziegler-Heitbrock HW, Thiel E, F\u00fctterer A, Herzog V, Wirtz A, Riethm\u00fcller G. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int J Cancer. 1988, 41:456-61. 10.1002\/ijc.2910410324","journal-title":"Int J Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(96)00129-4","article-title":"A model system in haematology and immunology: the human monocytic cell line MONO-MAC-1","volume":"21","author":"Steube KG","year":"1997","unstructured":"Steube KG, Teepe D, Meyer C, Zaborski M, Drexler HG. A model system in haematology and immunology: the human monocytic cell line MONO-MAC-1. Leuk Res. 1997, 21:327-35. 10.1016\/S0145-2126(96)00129-4","journal-title":"Leuk Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3892\/or.14.4.901","article-title":"Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124","volume":"14","author":"Smardov\u00e1 J","year":"2005","unstructured":"Smardov\u00e1 J, Pavlov\u00e1 S, Svit\u00e1kov\u00e1 M, Grochov\u00e1 D, Ravcukov\u00e1 B. Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124. Oncol Rep. 2005, 14:901-7. 10.3892\/or.14.4.901","journal-title":"Oncol Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2022.03.007","article-title":"Presence of mutant p53 increases stem cell frequency and is associated with reduced binding to classic TP53 binding sites in cell lines and primary AMLs","volume":"110","author":"Gerritsen M","year":"2022","unstructured":"Gerritsen M, Hilgendorf S, Yi G, Wierenga AT, Schuringa JJ, Martens JH, Vellenga E. Presence of mutant p53 increases stem cell frequency and is associated with reduced binding to classic TP53 binding sites in cell lines and primary AMLs. Exp Hematol. 2022, 110:39-46. 10.1016\/j.exphem.2022.03.007","journal-title":"Exp Hematol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400768","article-title":"Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23)","volume":"11","author":"Matsuo Y","year":"1997","unstructured":"Matsuo Y, MacLeod RA, Uphoff CC, et al.. Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia. 1997, 11:1469-77. 10.1038\/sj.leu.2400768","journal-title":"Leukemia"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.10161","article-title":"Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C\/EBPalpha gene","volume":"36","author":"Asou H","year":"2003","unstructured":"Asou H, Gombart AF, Takeuchi S, et al.. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C\/EBPalpha gene. Genes Chromosomes Cancer. 2003, 36:167-74. 10.1002\/gcc.10161","journal-title":"Genes Chromosomes Cancer"},{"key":"ref26","article-title":"The t(8;21) translocation is not consistently associated with high Bcl-2 expression in de novo acute myeloid leukemias of adults","volume":"4","author":"Banker DE","year":"1998","unstructured":"Banker DE, Radich J, Becker A, Kerkof K, Norwood T, Willman C, Appelbaum FR. The t(8;21) translocation is not consistently associated with high Bcl-2 expression in de novo acute myeloid leukemias of adults. Clin Cancer Res. 1998, 4:3051-62.","journal-title":"Clin Cancer Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V70.1.192.192","article-title":"Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines","volume":"70","author":"Lange B","year":"1987","unstructured":"Lange B, Valtieri M, Santoli D, et al.. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood. 1987, 70:192-9. 10.1182\/blood.V70.1.192.192","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0197-2","article-title":"Establishment and genetic characterization of a novel mixed-phenotype acute leukemia cell line with EP300-ZNF384 fusion","volume":"8","author":"Ping N","year":"2015","unstructured":"Ping N, Qiu H, Wang Q, et al.. Establishment and genetic characterization of a novel mixed-phenotype acute leukemia cell line with EP300-ZNF384 fusion. J Hematol Oncol. 2015, 8:100. 10.1186\/s13045-015-0197-2","journal-title":"J Hematol Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33143-w","article-title":"Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia","volume":"13","author":"Zhao X","year":"2022","unstructured":"Zhao X, Wang P, Diedrich JD, et al.. Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia. Nat Commun. 2022, 13:5401. 10.1038\/s41467-022-33143-w","journal-title":"Nat Commun"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.612880","article-title":"FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies","volume":"10","author":"Kennedy VE","year":"2020","unstructured":"Kennedy VE, Smith CC. FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies. Front Oncol. 2020, 10:612880. 10.3389\/fonc.2020.612880","journal-title":"Front Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0876","article-title":"FLT3 inhibitors in acute myeloid leukemia: current status and future directions","volume":"16","author":"Larrosa-Garcia M","year":"2017","unstructured":"Larrosa-Garcia M, Baer MR. FLT3 inhibitors in acute myeloid leukemia: current status and future directions. Mol Cancer Ther. 2017, 16:991-1001. 10.1158\/1535-7163.MCT-16-0876","journal-title":"Mol Cancer Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0470-z","article-title":"Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia","volume":"35","author":"Mori M","year":"2017","unstructured":"Mori M, Kaneko N, Ueno Y, et al.. Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017, 35:556-65. 10.1007\/s10637-017-0470-z","journal-title":"Invest New Drugs"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver N","year":"2021","unstructured":"Daver N, Venugopal S, Ravandi F. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J. 2021, 11:104. 10.1038\/s41408-021-00495-3","journal-title":"Blood Cancer J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang W","year":"2013","unstructured":"Yang W, Soares J, Greninger P, et al.. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013, 41:D955-61. 10.1093\/nar\/gks1111","journal-title":"Nucleic Acids Res"},{"key":"ref35","unstructured":"Genomics of drug sensitivity in cancer, version 8.5. (2023). Accessed. September 22, 2025: http:\/\/www.cancerrxgene.org."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone RM","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, et al.. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017, 377:454-64. 10.1056\/NEJMoa1614359","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000606","article-title":"European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis","volume":"4","author":"Tzogani K","year":"2019","unstructured":"Tzogani K, Yu Y, Meulendijks D, et al.. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis. ESMO Open. 2019, 4:000606. 10.1136\/esmoopen-2019-000606","journal-title":"ESMO Open"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-745133","article-title":"Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor","volume":"129","author":"Lee LY","year":"2017","unstructured":"Lee LY, Hernandez D, Rajkhowa T, et al.. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood. 2017, 129:257-60. 10.1182\/blood-2016-10-745133","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3114","article-title":"Dual inhibition of FLT3 and AXL by gilteritinib overcomes hematopoietic niche-driven resistance mechanisms in FLT3-ITD acute myeloid leukemia","volume":"27","author":"Dumas PY","year":"2021","unstructured":"Dumas PY, Villacreces A, Guitart AV, et al.. Dual inhibition of FLT3 and AXL by gilteritinib overcomes hematopoietic niche-driven resistance mechanisms in FLT3-ITD acute myeloid leukemia. Clin Cancer Res. 2021, 27:6012-25. 10.1158\/1078-0432.CCR-20-3114","journal-title":"Clin Cancer Res"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.105","article-title":"Quizartinib for the treatment of FLT3\/ITD acute myeloid leukemia","volume":"10","author":"Levis M","year":"2014","unstructured":"Levis M. Quizartinib for the treatment of FLT3\/ITD acute myeloid leukemia. Future Oncol. 2014, 10:1571-9. 10.2217\/fon.14.105","journal-title":"Future Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01148-x","article-title":"Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial","volume":"35","author":"R\u00f6llig C","year":"2021","unstructured":"R\u00f6llig C, Serve H, Noppeney R, et al.. Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. Leukemia. 2021, 35:2517-25. 10.1038\/s41375-021-01148-x","journal-title":"Leukemia"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert A","year":"2020","unstructured":"Burchert A, Bug G, Fritz LV, et al.. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020, 38:2993-3002. 10.1200\/JCO.19.03345","journal-title":"J Clin Oncol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.2147\/BLCTT.S281252","article-title":"FLT3 inhibitors as maintenance therapy after allogeneic stem-cell transplantation","volume":"12","author":"Blackmon A","year":"2022","unstructured":"Blackmon A, Aldoss I, Ball BJ. FLT3 inhibitors as maintenance therapy after allogeneic stem-cell transplantation. Blood Lymphat Cancer. 2022, 12:137-47. 10.2147\/BLCTT.S281252","journal-title":"Blood Lymphat Cancer"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-513044","article-title":"Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia","volume":"122","author":"Zimmerman EI","year":"2013","unstructured":"Zimmerman EI, Turner DC, Buaboonnam J, et al.. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood. 2013, 122:3607-15. 10.1182\/blood-2013-07-513044","journal-title":"Blood"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-529313","article-title":"Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants","volume":"123","author":"Galanis A","year":"2014","unstructured":"Galanis A, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J, Levis M. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood. 2014, 123:94-100. 10.1182\/blood-2013-10-529313","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112493","article-title":"Molecular mechanisms of resistance to FLT3 inhibitors in acute myeloid leukemia: ongoing challenges and future treatments","volume":"9","author":"Scholl S","year":"2020","unstructured":"Scholl S, Fleischmann M, Schnetzke U, Heidel FH. Molecular mechanisms of resistance to FLT3 inhibitors in acute myeloid leukemia: ongoing challenges and future treatments. Cells. 2020, 9:2493. 10.3390\/cells9112493","journal-title":"Cells"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-605808","article-title":"Secondary mutations as mediators of resistance to targeted therapy in leukemia","volume":"125","author":"Daver N","year":"2015","unstructured":"Daver N, Cortes J, Ravandi F, Patel KP, Burger JA, Konopleva M, Kantarjian H. Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood. 2015, 125:3236-45. 10.1182\/blood-2014-10-605808","journal-title":"Blood"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2148","article-title":"Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia","volume":"64","author":"Cools J","year":"2004","unstructured":"Cools J, Mentens N, Furet P, et al.. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res. 2004, 64:6385-9. 10.1158\/0008-5472.CAN-04-2148","journal-title":"Cancer Res"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08263-x","article-title":"Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms","volume":"10","author":"Zhang H","year":"2019","unstructured":"Zhang H, Savage S, Schultz AR, et al.. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat Commun. 2019, 10:244. 10.1038\/s41467-018-08263-x","journal-title":"Nat Commun"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"McMahon CM","year":"2019","unstructured":"McMahon CM, Ferng T, Canaani J, et al.. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 2019, 9:1050-63. 10.1158\/2159-8290.CD-18-1453","journal-title":"Cancer Discov"},{"key":"ref51","article-title":"Bone marrow stroma protects FLT3 acute myeloid leukemia (AML) through CYP3A4-mediated drug metabolization of FLT3 tyrosine kinase inhibitors (TKIs)","volume":"130","author":"Chang Y-T","year":"2017","unstructured":"Chang Y-T, Hernandez D, Ghiaur G, Levis MJ, Jones RJ. Bone marrow stroma protects FLT3 acute myeloid leukemia (AML) through CYP3A4-mediated drug metabolization of FLT3 tyrosine kinase inhibitors (TKIs). Blood. 2017, 130:2519.","journal-title":"Blood"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-266742","article-title":"FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo","volume":"117","author":"Sato T","year":"2011","unstructured":"Sato T, Yang X, Knapper S, et al.. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood. 2011, 117:3286-93. 10.1182\/blood-2010-01-266742","journal-title":"Blood"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-3569","article-title":"FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia","volume":"76","author":"Traer E","year":"2016","unstructured":"Traer E, Martinez J, Javidi-Sharifi N, et al.. FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia. Cancer Res. 2016, 76:6471-82. 10.1158\/0008-5472.CAN-15-3569","journal-title":"Cancer Res"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12599","article-title":"Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase","volume":"164","author":"Yang X","year":"2014","unstructured":"Yang X, Sexauer A, Levis M. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase. Br J Haematol. 2014, 164:61-72. 10.1111\/bjh.12599","journal-title":"Br J Haematol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.5.1953","article-title":"Dramatic increase in the numbers of functionally mature dendritic cells in FLT3 ligand-treated mice: multiple dendritic cell subpopulations identified","volume":"184","author":"Maraskovsky E","year":"1996","unstructured":"Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ. Dramatic increase in the numbers of functionally mature dendritic cells in FLT3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med. 1996, 184:1953-62. 10.1084\/jem.184.5.1953","journal-title":"J Exp Med"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.3.878","article-title":"In vivo generation of human dendritic cell subsets by Flt3 ligand","volume":"96","author":"Maraskovsky E","year":"2000","unstructured":"Maraskovsky E, Daro E, Roux E, et al.. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood. 2000, 96:878-84. 10.1182\/blood.V96.3.878","journal-title":"Blood"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1231-2","article-title":"Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication","volume":"90","author":"Rickmann M","year":"2011","unstructured":"Rickmann M, Krauter J, Stamer K, et al.. Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication. Ann Hematol. 2011, 90:1047-58. 10.1007\/s00277-011-1231-2","journal-title":"Ann Hematol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0317","article-title":"The irreversible FLT3 inhibitor FF-10101 is active against a diversity of FLT3 inhibitor resistance mechanisms","volume":"21","author":"Ferng TT","year":"2022","unstructured":"Ferng TT, Terada D, Ando M, et al.. The irreversible FLT3 inhibitor FF-10101 is active against a diversity of FLT3 inhibitor resistance mechanisms. Mol Cancer Ther. 2022, 21:844-54. 10.1158\/1535-7163.MCT-21-0317","journal-title":"Mol Cancer Ther"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-786657","article-title":"A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations","volume":"131","author":"Yamaura T","year":"2018","unstructured":"Yamaura T, Nakatani T, Uda K, et al.. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations. Blood. 2018, 131:426-38. 10.1182\/blood-2017-05-786657","journal-title":"Blood"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281216","article-title":"A phase Ib trial of mivavotinib (TAK-659), a dual SYK\/FLT3 inhibitor, in patients with relapsed\/refractory acute myeloid leukemia","volume":"108","author":"Pratz KW","year":"2023","unstructured":"Pratz KW, Kaplan J, Levy M, et al.. A phase Ib trial of mivavotinib (TAK-659), a dual SYK\/FLT3 inhibitor, in patients with relapsed\/refractory acute myeloid leukemia. Haematologica. 2023, 108:705-16. 10.3324\/haematol.2022.281216","journal-title":"Haematologica"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24747","article-title":"A novel, dual pan-PIM\/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia","volume":"9","author":"Czardybon W","year":"2018","unstructured":"Czardybon W, Windak R, Go\u0142as A, et al.. A novel, dual pan-PIM\/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. Oncotarget. 2018, 9:16917-31. 10.18632\/oncotarget.24747","journal-title":"Oncotarget"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000912","article-title":"BCL2 inhibition: a new paradigm for the treatment of AML and beyond","volume":"7","author":"Wei AH","year":"2023","unstructured":"Wei AH, Roberts AW. BCL2 inhibition: a new paradigm for the treatment of AML and beyond. Hemasphere. 2023, 7:e912. 10.1097\/HS9.0000000000000912","journal-title":"Hemasphere"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-3057","article-title":"Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells","volume":"22","author":"Niu X","year":"2016","unstructured":"Niu X, Zhao J, Ma J, et al.. Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells. Clin Cancer Res. 2016, 22:4440-51. 10.1158\/1078-0432.CCR-15-3057","journal-title":"Clin Cancer Res"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-196055","article-title":"FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation","volume":"114","author":"Yoshimoto G","year":"2009","unstructured":"Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, et al.. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood. 2009, 114:5034-43. 10.1182\/blood-2008-12-196055","journal-title":"Blood"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0832","article-title":"Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia","volume":"25","author":"Ma J","year":"2019","unstructured":"Ma J, Zhao S, Qiao X, et al.. Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia. Clin Cancer Res. 2019, 25:6815-26. 10.1158\/1078-0432.CCR-19-0832","journal-title":"Clin Cancer Res"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00973-4","article-title":"Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia","volume":"13","author":"Brinton LT","year":"2020","unstructured":"Brinton LT, Zhang P, Williams K, et al.. Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia. J Hematol Oncol. 2020, 13:139. 10.1186\/s13045-020-00973-4","journal-title":"J Hematol Oncol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00578-4","article-title":"FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation","volume":"6","author":"Zhu R","year":"2021","unstructured":"Zhu R, Li L, Nguyen B, et al.. FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation. Signal Transduct Target Ther. 2021, 6:186. 10.1038\/s41392-021-00578-4","journal-title":"Signal Transduct Target Ther"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.244020","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models","volume":"106","author":"Singh Mali R","year":"2021","unstructured":"Singh Mali R, Zhang Q, DeFilippis RA, et al.. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica. 2021, 106:1034-46. 10.3324\/haematol.2019.244020","journal-title":"Haematologica"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/382173-current-therapeutic-strategies-for-flt3-mutated-acute-myeloid-leukemia-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T16:59:41Z","timestamp":1761325181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/382173-current-therapeutic-strategies-for-flt3-mutated-acute-myeloid-leukemia-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":68,"URL":"https:\/\/doi.org\/10.7759\/cureus.95338","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,24]]}}}